Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
09 05 2020
Historique:
received: 09 03 2020
revised: 02 05 2020
accepted: 08 05 2020
entrez: 14 5 2020
pubmed: 14 5 2020
medline: 27 2 2021
Statut: epublish

Résumé

Chimeric antigen receptor (CAR)-T cells have demonstrated significant clinical potential; however, their strong antitumor activity may cause severe adverse effects. To ensure efficacy and safe CAR-T cell therapy, it is important to understand CAR's structure-activity relationship. To clarify the role of hinge and transmembrane domains in CAR and CAR-T cell function, we generated different chimeras and analyzed their expression levels and antigen-specific activity on CAR-T cells. First, we created a basic CAR with hinge, transmembrane, and signal transduction domains derived from CD3ζ, then we generated six CAR variants whose hinge or hinge/transmembrane domains originated from CD4, CD8α, and CD28. CAR expression level and stability on the T cell were greatly affected by transmembrane rather than hinge domain. Antigen-specific functions of most CAR-T cells depended on their CAR expression levels. However, CARs with a CD8α- or CD28-derived hinge domain showed significant differences in CAR-T cell function, despite their equal expression levels. These results suggest that CAR signaling intensity into T cells was affected not only by CAR expression level, but also by the hinge domain. Our discoveries indicate that the hinge domain regulates the CAR signaling threshold and the transmembrane domain regulates the amount of CAR signaling via control of CAR expression level.

Identifiants

pubmed: 32397414
pii: cells9051182
doi: 10.3390/cells9051182
pmc: PMC7291079
pii:
doi:

Substances chimiques

RNA, Messenger 0
Receptors, Chimeric Antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Mol Ther Oncolytics. 2019 Aug 28;15:60-68
pubmed: 31650026
Nat Rev Immunol. 2012 Mar 22;12(4):269-81
pubmed: 22437939
Nat Rev Clin Oncol. 2018 Jan;15(1):31-46
pubmed: 28857075
Biochem Biophys Res Commun. 2020 Jun 25;527(2):350-357
pubmed: 32216966
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025
pubmed: 30979735
Cancer Immunol Immunother. 2015 Dec;64(12):1623-35
pubmed: 26515978
Cell. 2008 Nov 14;135(4):702-13
pubmed: 19013279
Mol Ther Oncolytics. 2016 Nov 16;3:16024
pubmed: 27909701
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
pubmed: 8421711
JCI Insight. 2018 Jan 11;3(1):
pubmed: 29321369
Clin Cancer Res. 2013 Jun 15;19(12):3153-64
pubmed: 23620405
Mol Ther Methods Clin Dev. 2018 Dec 31;12:145-156
pubmed: 30666307
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Sci China Life Sci. 2016 Apr;59(4):349-59
pubmed: 27009301
Cancer Gene Ther. 2013 Jan;20(1):57-64
pubmed: 23175243
Cancers (Basel). 2020 Jan 03;12(1):
pubmed: 31947775
Biochem Biophys Res Commun. 2010 Mar 26;394(1):54-8
pubmed: 20171182
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Mol Cell Biol. 1998 Jan;18(1):558-65
pubmed: 9418902
Biochem Biophys Res Commun. 2004 Apr 23;317(1):60-7
pubmed: 15047148
Cell. 2001 Nov 16;107(4):501-12
pubmed: 11719190
Mol Ther. 2010 Apr;18(4):843-51
pubmed: 20179677
Nature. 2017 Mar 2;543(7643):113-117
pubmed: 28225754
Annu Rev Cell Dev Biol. 2000;16:557-89
pubmed: 11031247
Oncoimmunology. 2016 Nov 8;5(12):e1253656
pubmed: 28180032
Nat Cell Biol. 2009 Nov;11(11):1332-9
pubmed: 19855387
J Immunol. 2010 Jun 15;184(12):6938-49
pubmed: 20483753
Biochem Biophys Res Commun. 2016 Apr 22;473(1):73-79
pubmed: 26993168
J Immunol. 2004 Jan 1;172(1):104-13
pubmed: 14688315
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
Am J Cancer Res. 2016 Jan 15;6(2):403-24
pubmed: 27186412
Cells. 2019 May 17;8(5):
pubmed: 31108883
Cell Immunol. 2006 Dec;244(2):125-9
pubmed: 17467674
Cancer Immunol Res. 2015 Apr;3(4):368-79
pubmed: 25576337
Cancer Res. 2015 Sep 1;75(17):3596-607
pubmed: 26330166
Immunity. 1995 Jun;2(6):639-44
pubmed: 7796297
J Hematol Oncol. 2018 Feb 13;11(1):22
pubmed: 29433552
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797

Auteurs

Kento Fujiwara (K)

Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.

Ayaka Tsunei (A)

Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.

Hotaka Kusabuka (H)

Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.

Erika Ogaki (E)

Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.

Masashi Tachibana (M)

Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.

Naoki Okada (N)

Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH